SCHEMBL5537880

SCHEMBL5537880

O=[C]OCc1csc(-c2ccc(Br)cc2Br)n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.42
ALDH1A1 P00352 2/20 0.42
LMNA P02545 1/20 0.42
PPARG P37231 1/20 0.42
GFER P55789 1/20 0.42
NCOA2 Q15596 1/20 0.42
NCOA1 Q15788 1/20 0.42
RXFP1 Q9HBX9 1/20 0.42
DRD2 P14416 3/20 0.36
DRD4 P21917 3/20 0.36
DRD3 P35462 3/20 0.36
SHMT1 P34896 2/20 0.32
SHMT2 P34897 2/20 0.32
RAB9A P51151 3/20 0.32
ABCB1 P08183 1/20 0.31
L3MBTL1 Q9Y468 3/20 0.31
NPC1 O15118 1/20 0.31
TSHR P16473 1/20 0.31
MAPK1 P28482 1/20 0.31
KDM4E B2RXH2 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5539775 0.83 ALDH1A1 (0.40) MAPTALDH1A1LMNAPPARGGFER
SCHEMBL2094557 0.80 ALDH1A1 (0.45) MAPTALDH1A1LMNAPPARGGFER
SCHEMBL5541183 0.76 CYP17A1 (0.39) MAPTALDH1A1LMNARAB9ANPC1
SCHEMBL5546130 0.73 RAB9A (0.56) MAPTALDH1A1LMNADRD2DRD4
SCHEMBL5535352 0.72 L3MBTL1 (0.61) MAPTALDH1A1LMNAPPARGRXFP1
SCHEMBL5547627 0.71 ALDH1A1 (0.39) MAPTALDH1A1LMNASHMT2RAB9A
SCHEMBL5541827 0.70 GFER (0.60) MAPTALDH1A1LMNAGFERRAB9A
SCHEMBL5547788 0.69 SMN1; SMN2 (0.35) MAPTALDH1A1LMNARAB9ANPC1
SCHEMBL5537339 0.69 LMNA (0.53) MAPTLMNAPPARGGFERRXFP1
SCHEMBL5539845 0.69 PIM1 (0.43) MAPTALDH1A1LMNARAB9AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102532162-B 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMA CO LTD 2015-05-27 CN disclosed
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 MAPT 4117/4885ALDH1A1 355/4885LMNA 4152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.